Literature DB >> 31848709

Macrophage-tumor cell interaction promotes ATRT progression and chemoresistance.

Viktoria Melcher1, Monika Graf1, Marta Interlandi1,2, Natalia Moreno1, Flavia W de Faria1, Su Na Kim1, Dennis Kastrati1, Sonja Korbanka1, Amelie Alfert1, Joachim Gerß3, Gerd Meyer Zu Hörste4, Wolfgang Hartmann5, Michael C Frühwald6,7, Martin Dugas2, Ulrich Schüller8,9,10, Martin Hasselblatt11, Thomas K Albert1, Kornelius Kerl12.   

Abstract

Atypical teratoid/rhabdoid tumors (ATRT) are known for their heterogeneity concerning pathophysiology and outcome. However, predictive factors within distinct subgroups still need to be uncovered. Using multiplex immunofluorescent staining and single-cell RNA sequencing we unraveled distinct compositions of the immunological tumor microenvironment (TME) across ATRT subgroups. CD68+ cells predominantly infiltrate ATRT-SHH and ATRT-MYC and are a negative prognostic factor for patients' survival. Within the murine ATRT-MYC and ATRT-SHH TME, Cd68+ macrophages are core to intercellular communication with tumor cells. In ATRT-MYC distinct tumor cell phenotypes express macrophage marker genes. These cells are involved in the acquisition of chemotherapy resistance in our relapse xenograft mouse model. In conclusion, the tumor cell-macrophage interaction contributes to ATRT-MYC heterogeneity and potentially to tumor recurrence.

Entities:  

Keywords:  Atypical teratoid/rhabdoid tumor; Cell interaction; Chemotherapy resistance; Single-cell RNA sequencing; Tumor microenvironment; Tumor-associated macrophages

Mesh:

Substances:

Year:  2019        PMID: 31848709     DOI: 10.1007/s00401-019-02116-7

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  10 in total

1.  SWI/SNF complex heterogeneity is related to polyphenotypic differentiation, prognosis, and immune response in rhabdoid tumors.

Authors:  Pooja Panwalkar; Drew Pratt; Chan Chung; Derek Dang; Paul Le; Daniel Martinez; Jill M Bayliss; Kyle S Smith; Mike Adam; Steven Potter; Paul A Northcott; Leo Mascarenhas; Jared Shows; Bruce Pawel; Ashley Margol; Annie Huang; Alexander R Judkins; Sriram Venneti
Journal:  Neuro Oncol       Date:  2020-06-09       Impact factor: 12.300

Review 2.  Engineering in vitro immune-competent tissue models for testing and evaluation of therapeutics.

Authors:  Jennifer H Hammel; Jonathan M Zatorski; Sophie R Cook; Rebecca R Pompano; Jennifer M Munson
Journal:  Adv Drug Deliv Rev       Date:  2022-01-11       Impact factor: 15.470

3.  A Novel Matrisomal-Related LncRNA Signature Associated With Survival Outcome and Immune Evasion in Patients With Gastric Cancer.

Authors:  Yuan Yang; Li Shi; Jun Zhang; Ya Zheng; Guozhi Wu; Jie Sun; Min Liu; Zhaofeng Chen; Yuping Wang; Rui Ji; Qinghong Guo; Yongning Zhou
Journal:  Front Oncol       Date:  2022-06-24       Impact factor: 5.738

Review 4.  The Cellular Tumor Immune Microenvironment of Childhood Solid Cancers: Informing More Effective Immunotherapies.

Authors:  Malcolm Holterhus; Bianca Altvater; Sareetha Kailayangiri; Claudia Rossig
Journal:  Cancers (Basel)       Date:  2022-04-27       Impact factor: 6.575

5.  An extracellular vesicle-related gene expression signature identifies high-risk patients in medulloblastoma.

Authors:  Thomas K Albert; Marta Interlandi; Martin Sill; Monika Graf; Natalia Moreno; Kerstin Menck; Astrid Rohlmann; Viktoria Melcher; Sonja Korbanka; Gerd Meyer Zu Hörste; Tobias Lautwein; Michael C Frühwald; Christian F Krebs; Dörthe Holdhof; Melanie Schoof; Annalen Bleckmann; Markus Missler; Martin Dugas; Ulrich Schüller; Natalie Jäger; Stefan M Pfister; Kornelius Kerl
Journal:  Neuro Oncol       Date:  2021-04-12       Impact factor: 12.300

Review 6.  CAR T Cell Therapy for Pediatric Brain Tumors.

Authors:  John D Patterson; Jeffrey C Henson; Rebecca O Breese; Kevin J Bielamowicz; Analiz Rodriguez
Journal:  Front Oncol       Date:  2020-08-12       Impact factor: 6.244

Review 7.  Ocoxin as a complement to first line treatments in cancer.

Authors:  Aitor Benedicto; Eduardo Sanz; Joana Márquez
Journal:  Int J Med Sci       Date:  2021-01-01       Impact factor: 3.738

8.  InterCellar enables interactive analysis and exploration of cell-cell communication in single-cell transcriptomic data.

Authors:  Marta Interlandi; Kornelius Kerl; Martin Dugas
Journal:  Commun Biol       Date:  2022-01-11

9.  Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors.

Authors:  Ana Marcu; Andreas Schlosser; Anne Keupp; Nico Trautwein; Pascal Johann; Matthias Wölfl; Johanna Lager; Camelia Maria Monoranu; Juliane S Walz; Lisa M Henkel; Jürgen Krauß; Martin Ebinger; Martin Schuhmann; Ulrich Wilhelm Thomale; Torsten Pietsch; Erdwine Klinker; Paul G Schlegel; Florian Oyen; Yair Reisner; Hans-Georg Rammensee; Matthias Eyrich
Journal:  J Immunother Cancer       Date:  2021-10       Impact factor: 13.751

10.  Single-cell transcriptomics identifies potential cells of origin of MYC rhabdoid tumors.

Authors:  Monika Graf; Marta Interlandi; Natalia Moreno; Dörthe Holdhof; Carolin Göbel; Viktoria Melcher; Julius Mertins; Thomas K Albert; Dennis Kastrati; Amelie Alfert; Till Holsten; Flavia de Faria; Michael Meisterernst; Claudia Rossig; Monika Warmuth-Metz; Johannes Nowak; Gerd Meyer Zu Hörste; Chloe Mayère; Serge Nef; Pascal Johann; Michael C Frühwald; Martin Dugas; Ulrich Schüller; Kornelius Kerl
Journal:  Nat Commun       Date:  2022-03-22       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.